A proteomic study on cell cycle progression of endothelium exposed to tumor conditioned medium and the possible role of cyclin D1/E

Clinical Hemorheology and Microcirculation

Volumn 29, Issue 3-4, 2003, Pages 383-390

  Li, Ailing ^a   Li, Hongwei ^a   Jin, Gang ^b   Xiu, Ruijuan ^a  

^a Chinese Academy of Medical Sciences   (China)

^b INSTITUTE OF MECHANICS   (China)

Author keywords

2 DE; Cell cycle; Endothelium; Tumor conditioned medium; Western blot

Indexed keywords

ANGIOGENIC FACTOR; CYCLIN D1; CYCLIN E; PROTEIN;

CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL LINE; CELL LYSATE; CONFERENCE PAPER; ENDOTHELIUM; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEOMICS; REGULATORY MECHANISM; UMBILICAL VEIN; WESTERN BLOTTING;

ANGIOGENESIS INDUCING AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYCLIN D1; CYCLIN E; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; HYDROGEN PEROXIDE; MITOSIS; PROTEIN BIOSYNTHESIS; PROTEINS; PROTEOMICS; SUBTRACTION TECHNIQUE; UMBILICAL VEINS;

EID: 0942298997     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. K.J. Kim, B. Li, J. Winer et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo, Nature 362 (1993), 841-844.
2. J. Folkman, Tumor angiogenesis: therapeutuc implication, N. Engl. J. Med. 285 (1971), 1182-1186.
3. J. Folkman, Antiangiogenesis: new concept for therapy of solid tumors, Ann. Surg. 175 (1972), 408-416.
4. R.J. Xiu, C.G. Duan and G.F. Mu, The study on angiogenesis induced by SP2/0 and Hela cell, Zhong. Hua. Zhong. Liu. 9 (1987), 95-97.
5. R.J. Xiu, Tumor and microcirculation, Zhong. Hua. Zhong. Liu. 6 (1985), 257-260.
6. R. Kerbel and J. Folkman, Clinical translation of angiogenesis inhibitors, Cancer 2 (2002), 727-739.
7. R.L. Engerman, D. Pfaffenbach and D. Davis, Cell turnover of capillary, Lab. Invest. 17 (1967), 738-743.
8. C.J. Sherr, D-type cyclin Ds, TIBS 20 (1995), 187-190.
9. C.J. Sherr, Cancer cell cycles, Science 274 (1996), 1672-1677.
10. C.J. Sherr and J.M. Roberts, Inhibitors of mammalian G1 cyclin-dependent kinases, Genes. Dev. 9 (1995), 1149-1163.
11. A. Pedram, M. Razandi and E.R. Levin, Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis, Endocrinology 142 (2001), 1578-1586.
12. R. Pai, I.L. Szabo, H. Kawanaka et al., Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action?, Mol. Cell. Biol. Res. Commun. 4 (2000), 111-116.
13. WAF1/CIP1, PNAS 97 (2000), 6427-6432.
14. WAF1/CIP1 for endothelial cell growth arrest, PNAS 97 (2000), 12782-12787.
15. Y.L. Guo, S.J. Wang and R.W. Colman, Kininostatin, an angiogenic inhitor, inhibits proliferation and induces apoptosis of human endothelial cells, Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1427-1433.
16. (WAF1/CIP1), Cancer Lett. 189 (2003), 39-48.
17. E.A. Jaffe, R.L. Nachman, C.G. Becker and C.R. Minick, Culture of human endothelial cells derived from umbilical veins: identification by morphological and immunological criteria, J. Clin. Invest. 52 (1973), 2745-2756.
18. P.W. Hewett, Identification of tumour-induced changes in endothelial cell surface protein expression: an in vitro model, Int. J. Biochem. & Cell. Biol. 33 (2001), 325-335.
19. G.D. Yancopoulos, S. Davis, N.W. Gale et al., Vascular-specific growth factors and blood vessel formation, Nature 407 (2000), 242-248.
20. P.W. Hewett and J.C. Murray, Modulation of human endothelial cell procoagulant activity in tumour models in vitro, Int. J. Cancer 66 (1996), 784-789.
21. Q.D. Wu, J.H. Wang, D. Bouchier-Hayes and H.P. Redmond, Neutrophil-induced transmigration of tumor-conditioned medium is facilitated by granulocyte-macrophage colony-stimulating factor, Eur. J. Surg. 166 (2000), 361-366.
22. S. Lang, A. Hartner, R.B. Sterzel and H.O. Schocklmann, Requirement of cyclin D1 in mesangial cell mitogenesis, J. Am. Soc. Nephrol. 11 (2000), 1398-1408.
23. M. Kornmann, N. Arber and M. Korc, Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum, J. Clin. Invest. 101 (1998), 344-352.
24. M. Kornmann, K.D. Danenberg, N. Arber et al., Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes, Cancer Res. 59 (1999), 3505-3511.
25. N. Arber, Y. Doki, E.K. Han et al., Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells, Cancer Res. 57 (1997), 1569-1574.
26. P. Zhou, W. Jiang, Y.J. Zhang et al., Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells, Oncogene 11 (1995), 571-580.
27. Y. Saikawa, T. Kubota, Y. Otani et al., Cyclin D1 antisense oligonucleotide inhibits cell growth stimulated by epidermal growth factor and induces apoptosis of gastric cancer cells, Jpn. J. Cancer Res. 92 (2001), 1102-1109.